What Savara Investors Should Know About This 580,187-Option Exercise and FDA Tim

On June 22, 2026, David Lowrance, the Chief Financial Officer of Savara (NASDAQ:SVRA), executed the exercise of 580,187 options on Common Stock followed by the sale of 394,528 shares in the open market, as reported in this SEC Form 4 filing.

Post-transaction value (direct ownership)

Transaction and post-transaction values based on SEC Form 4 weighted average purchase price of $5.68 on June 22, 2026.

How does this transaction compare to Lowrance's historical activity?The 394,528-share sale is materially larger than Lowrance's previous asles, reflecting a liquidity move enabled by option exercises and a reduced remaining share base.

What is the significance of the option exercise and immediate sale structure?Lowrance exercised 580,187 options and immediately sold 394,528 shares, with 185,659 shares withheld for taxes; all shares sold and withheld were related to the option exercise and not to discretionary open-market sales of previously held stock.

What is Lowrance's ongoing equity exposure after this event?He continues to hold 536,032 shares of Common Stock directly after the transaction.

How did market conditions relate to the timing of the sale?The transaction occurred as t

Fuente original: Yahoo Finance (https://finance.yahoo.com/healthcare/articles/savara-investors-know-580-187-153409768.html)